Article Sidebar
Views PDF: 117
SURVIVAL RESULT AND ADVERSE EVENTS OF SECOND LINE OF TOPOTECAN IN RECURRENT/METASTATIC SMALL-CELL LUNG CANCER
Main Article Content
Abstract
Objective: Assessing treatment results and adverse events of second line Topotecan in patients with recurrent/metastatic small-cell lung cancer who had failed to doublet chemotherapy platinum – Etoposide at National Cancer Hospital. Patients and method: Retrospective and prospective analysis of 42 recurrent/metastatic small-cell lung cancer patients who had failed less than 6 months to doublet chemotherapy platinum – Etoposide, then treated with Topotecan at National Cancer Hospital from 01/2017 to 4/2022. Results: Mean age at diagnosis was 58.5 with male/female ratio: 2.4/1. The common symptoms were chest pain (73.8%), cough (64.3%) and dyspnea (47.6%) with brain and liver metastasis, accounted for 30.9% and 26.2%, respectively. Overall response rate (complete and partial response) was seen in 9 patients (21.4%) and 7 patients of stable disease (16.7%). Disease control rate was 38.1%. Symptoms relief was reported in the majority of patient with chemotherapy. Mean progression free survival (PFS) was 16.0 weeks. The most common adverse events (AEs) were hematologic AEs with neutropenia grade 3 (19.0%) and grade 4 (47.6%). Diarrhea and nausea grade 3-4 was reported in minor patients (less than 5%). Conclusion: Small-cell lung cancer is more prevalent in the old men with clinical presentation of chest pain and dyspnea. Second line of Topotecan had improved the clinical symptoms with disease response rate 38.1% and the most common adverse events (AEs) was neutropenia.
Article Details
Keywords
Recurrent/metastatic small-cell lung cancer, second line of Topotecan
References
2. Mascaux, C., Paesmans, M., Berghmans, T. et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000; 30: 23–26
3. Rossi, A., Di Maio, M., Chiodini, P. et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30: 1692–1698
4. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; 379:2220.
5. Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17:1147.
6. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441.
7. Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658.
8. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25:2086.